The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis
Open accessAbstract
Tuberculosis kills more people than any other infectious disease. Three pivotal trials testing 4-month regimens failed to meet non-inferiority margins; however, approximately four-fifths of participants were cured. Through a pooled analysis of patient-level data with external validation, we identify populations eligible for 4-month treatment, define phenotypes that are hard to treat and evaluate the impact of adherence and dosing strategy on outcomes. In 3,405 participants included in analyses, baseline smear grade of 3+ relative to <2+, HIV seropositivity and adherence of ≤90% were significant risk factors for unfavorable outcome. Four-month regimens were non-inferior in participants with minimal disease defined by <2+ sputum smear grade or non-cavitary disease. A hard-to-treat phenotype, defined by high smear grades and cavitation, may require durations >6 months to cure all. Regimen duration can be selected in order to improve outcomes, providing a stratified medicine approach as an alternative to the 'one-size-fits-all' treatment currently used worldwide.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistics in Medicine — Reporting of Subgroup Analyses in Clinical Trials
Wang, R., Lagakos, S. W., Ware, J. H., Hunter, D. J., & Drazen, J. M. (2007) · New England Journal of Medicine · doi:10.1056/nejmsr077003 · Cited by 1,445
Nahid, P., Dorman, S. E., Alipanah, N., Barry, P. M., Brozek, J. L., Cattamanchi, A., Chaisson, L. H., Chaisson, R. E., Daley, C. L., Grzemska, M., et al. (2016) · Clinical Infectious Diseases · doi:10.1093/cid/ciw376 · Cited by 1,170
Self-citationFox, W., Ellard, G. A., & Mitchison, D. A. (1999) · PubMed · Cited by 797
Four-Month Moxifloxacin-Based Regimens for Drug-Sensitive Tuberculosis
Gillespie, S. H., Crook, A. M., McHugh, T. D., Mendel, C. M., Meredith, S. K., Murray, S. R., Pappas, F., Phillips, P. P. J., & Nunn, A. J. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407426 · Cited by 645
Self-citationXie, J., & Liu, C. (2005) · Statistics in Medicine · doi:10.1002/sim.2174 · Cited by 510
High-Dose Rifapentine with Moxifloxacin for Pulmonary Tuberculosis
Jindani, A., Harrison, T. S., Nunn, A. J., Phillips, P. P. J., Churchyard, G. J., Charalambous, S., Hatherill, M., Geldenhuys, H., McIlleron, H. M., Zvada, S. P., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1314210 · Cited by 432
Self-citationA Four-Month Gatifloxacin-Containing Regimen for Treating Tuberculosis
Merle, C. S., Fielding, K., Sow, O. B., Gninafon, M., Lo, M. B., Mthiyane, T., Odhiambo, J., Amukoye, E., Bah, B., Kassa, F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315817 · Cited by 399
Self-citationSharing Clinical Trial Data: A Proposal From the International Committee of Medical Journal Editors
Taichman, D. B., Backus, J., Baethge, C., Bauchner, H., de Leeuw, P. W., Drazen, J. M., Fletcher, J., Frizelle, F. A., Groves, T., Haileamlak, A., et al. (2016) · JAMA · doi:10.1001/jama.2015.18164 · Cited by 254
Whither short-course chemotherapy?
Fox, W. (1981) · British Journal of Diseases of the Chest · doi:10.1016/0007-0971(81)90022-x · Cited by 215
Cited by
Furin, J., Cox, H., & Pai, M. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30308-3 · Cited by 873
Anti-tuberculosis treatment strategies and drug development: challenges and priorities
Dartois, V. A., & Rubin, E. J. (2022) · Nature Reviews Microbiology · doi:10.1038/s41579-022-00731-y · Cited by 490
Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline
Nahid, P., Mase, S. R., Migliori, G. B., Sotgiu, G., Bothamley, G. H., Brozek, J. L., Cattamanchi, A., Cegielski, J. P., Chen, L., Daley, C. L., et al. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201909-1874st · Cited by 462
Self-citationFrascella, B., Richards, A. S., Sossen, B., Emery, J. C., Odone, A., Law, I., Onozaki, I., Esmail, H., & Houben, R. M. G. J. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciaa1402 · Cited by 315
Vernon, A., Fielding, K., Savic, R., Dodd, L., & Nahid, P. (2019) · PLOS Medicine · doi:10.1371/journal.pmed.1002884 · Cited by 104
Self-citation
Metadata
- Authors
- Imperial, M. Z., Nahid, P., Phillips, P. P. J., Davies, G. R., Fielding, K., Hanna, D., Hermann, D., Wallis, R. S., Johnson, J. L., Lienhardt, C., & Savic, R. M.
- Venue
- Nature Medicine
- Published
- 2018-11
- Volume
- 24
- Issue
- 11
- Pages
- 1708-1715
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- OpenAlex
- W2895784427
- Cited by
- 360
- References
- 17
- FWCI
- 23.00
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis. https://app.cochat.ai/papers/10.1038/s41591-018-0224-2
- The paper
- Imperial, M. Z., Nahid, P., Phillips, P. P. J., Davies, G. R., Fielding, K., Hanna, D., Hermann, D., Wallis, R. S., Johnson, J. L., Lienhardt, C., & Savic, R. M. (2018). A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis. Nature Medicine. https://doi.org/10.1038/s41591-018-0224-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.